Halogenated Heteroaryl Kinase Inhibitor for Extended Sarcoma Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for soft tissue sarcomas, particularly angiosarcoma, are inadequate, with surgery, radiotherapy, and chemotherapy often failing to completely remove cancerous tissue and causing severe side effects, and cancers developing resistance to chemotherapeutic drugs.

Innovation Solution

A novel kinase inhibitor, compound E9, targeting SIK3 kinase, is used alone or in combination with other therapeutics to treat soft tissue sarcomas, offering prolonged progression-free survival and extended treatment response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgery, radiotherapy, and chemotherapy are used to treat soft tissue sarcomas, then tumor removal and treatment are achieved, but severe side effects occur and cancers develop resistance to chemotherapeutic drugs

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects and drug resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the molecular target parameter from conventional chemotherapy agents to a specific kinase inhibitor (SIK3 inhibitor) with a distinct chemical structure (compound E9). This parameter change in the therapeutic mechanism leads to improved treatment effectiveness while reducing the harmful effects of severe side effects and drug resistance associated with conventional chemotherapies.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If conventional chemotherapeutic drugs are used to treat sarcomas, then cancer cells are killed, but the treatment duration is limited and progression-free survival is short

Engineering Contradiction:

Improvetreatment response rateVSAvoidprogression-free survival

Core Design Contradiction:

ProductivityVSDuration of action of moving object

Solution Approach 1:

The kinase inhibitor compound E9 maintains continuous useful action by providing prolonged progression-free survival and extended treatment response. The compound continuously inhibits SIK3 kinase activity, preventing tumor progression over an extended period rather than providing only temporary relief like conventional chemotherapies.

Inventive Principle:

Principle #20Continuity of useful action

3Adaptability or versatility

If targeted therapies such as anti-angiogenic compounds are used, then specific molecular features are addressed, but treatment options remain limited and effectiveness varies

Engineering Contradiction:

Improvetargeted therapy specificityVSAvoidtreatment effectiveness consistency

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies universality by developing a kinase inhibitor that targets a fundamental signaling pathway (SIK3) that is broadly relevant across different sarcoma subtypes. This multi-functional approach addresses specific molecular features while maintaining consistent effectiveness across various soft tissue sarcoma types, improving both targeted therapy specificity and treatment effectiveness consistency.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP4643861A1A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors

Publication Date: 2025.11.05 IOMX THERAPEUTICS AG

Figure 1A
Figure 1B
Figure 1C

AI summary

The present invention relates to the treatment of soft tissue sarcomas and vascular tumors such as angiosarcoma, hemangiomas or hemangioendothelioma, using a halogenated heterocyclic kinase inhibitor. In particular, the invention relates to halogenated heterocyclic kinase inhibitor, optionally in combination with a second therapeutic for the treatment of soft tissue sarcomas or vascular tumors, such as angiosarcoma, hemangiomas or hemangioendotheliomas.